Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback